Expanding Oncology Testing And Genomic Profiling Will Widen Market Reach

Shared on01 May 25
Fair value Decreased 52%

Shared on24 Apr 25
Fair value Increased 103%

AnalystConsensusTarget made no meaningful changes to valuation assumptions.

Shared on17 Apr 25
Fair value Decreased 56%

Shared on09 Apr 25

AnalystConsensusTarget made no meaningful changes to valuation assumptions.

Shared on02 Apr 25
Fair value Decreased 2.97%

AnalystConsensusTarget made no meaningful changes to valuation assumptions.

Shared on26 Mar 25
Fair value Increased 135%

AnalystConsensusTarget made no meaningful changes to valuation assumptions.